New therapeutic options in DVT prophylaxis

Orthopedics

Volumn 23, Issue 6 SUPPL., 2000, Pages

  Wille Jørgensen, Peer ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

CONFERENCE PAPER; ELECTIVE SURGERY; HIGH RISK PATIENT; LUNG EMBOLISM; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; SURGICAL RISK; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS;

ANESTHESIA, CONDUCTION; ANTICOAGULANTS; BANDAGES; CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG COMBINATIONS; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HIRUDIN THERAPY; HIRUDINS; HUMANS; LOGISTIC MODELS; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0033917910     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Prevention of venous thromboembolism. International consensus statement (guidelines according to scientific evidence). Int Angiol. 1997; 16:3-38.
2. Clagett GP, Anderson FA Jr, Geerts W, et al. Prevention of venous thromboembolism. Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 1998; 114(5 suppl):531S-560S.
3. Second Thromboembolic Risk Factors (THRiFT II) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology. 1998; 13:87-97.
4. Murray DW, Britton AR, Bulstrode CJK. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br. 1996; 78:863-870.
5. Prentice C. Thromboprophylaxis in elective orthopedic surgery - what is the purpose? J Bone Joint Surg Br. 1997; 79B:889-890.
6. McGrath D, Dennyson WG, Rolland M. Death rate from pulmonary embolism following joint replacement surgery. J R Coll Surg Edinb. 1996; 41:265-266.
7. Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement. J Bone Joint Surg Br. 1997; 79:896-899.
8. Royal College of Surgeons. National confidential enquiry into postoperative deaths, 1991/1992. London RCS.
9. Karwinski B, Svendsen E. Comparison of clinical and postmortem diagnosis of pulmonary embolism. J Clin Pathol. 1989; 42:135-139.
10. Hunter JB, Frostick SP. Dalteparin (Fragmin) for the prevention of early mortality after orthopedic surgery. Thromb Haeost. 1995; 73:977.
11. Boneu B. New antithrombotic agents for the prevention and treatment of deep vein thrombosis. Haemostasis. 1996; 26(suppl 4):368-378.
12. Turpie AGG. Low molecular-weight heparin: from the bench to the orthopedic patient. Orthopedics. 1997; Feb(suppl):10-13.
13. Magnani HN, Beijering RJR, ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA: Hanley & Belfus Inc., 1997:487-500.
14. Leyvraz P, Bachmann F, Bohnet J, et al. Subcutaneous thromboembolic prophylaxis in total hip replacement: a comparison between the low-molecular weight heparinoid ORGARAN and heparin-dihydroergotamine. Br J Surg. 1992; 79:911-934.
15. Comp PC, Voegeli T, McCutchen JW, et al. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement. Orthopedics. 1998; 21:1123-1128.
16. Gent M, Hirsh J, Ginsberg JS, et al. Low-molecular-weight heparinoid Orgaran is more effective than Aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation. 1996; 93:80-84.
17. Gerhart TN, Yett HS, Robertson LK, et al. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep vein thrombosis in patients who are operated on for fracture of the hip. J Bone Joint Surg Am. 1991; 73:494.
18. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost. 1993; 70:554-561.
19. Rosenberg RD. The heparin-antithrombin system: A natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EX, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Co., 1987:1373-1392.
20. Eschenfelder V. Pharmacologic considerations in the development of hirudin and its derivatives for cardiovascular indications. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA: Hanley & Belfus Inc., 1997:161-174.
21. Eriksson BI, Ekman S, Kalebo P, et al. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996; 347:635-639.
22. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin. J Bone Joint Surg Am. 1997; 79A(3):326-333.
23. Eriksson BI, Wille-Jørgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weignt heparin to prevent thromboembolic complications after tolal hip replacement. N Engl J Med. 1997; 337(19):1329-1335.
24. Eriksson BI, Ekman S, Baur M, et al. Regional block anesthesia versus general anesthesia, are different antithrombotic drugs equally effective in patients undergoing total hip replacement? Thromb Haemost. 1997; suppl(July):487.